Novartis
NVS
875 hedge funds and large institutions have $22.5B invested in Novartis in 2014 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 315 increasing their positions, 335 reducing their positions, and 21 closing their positions.
157% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 21
71% more call options, than puts
Call options by funds: $187M | Put options by funds: $110M
22% more funds holding in top 10
Funds holding in top 10: 58 → 71 (+13)
3% more funds holding
Funds holding: 848 → 875 (+27)
2% more capital invested
Capital invested by funds: $22B → $22.5B (+$520M)
0.06% less ownership
Funds ownership: 9.79% → 9.72% (-0.06%)
6% less repeat investments, than reductions
Existing positions increased: 315 | Existing positions reduced: 335
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$213M |
| 2 |
TH
TCTC Holdings
Dallas,
Texas
|
+$38.5M |
| 3 |
PP
PDT Partners
New York
|
+$36.4M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$33.2M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$145M |
| 2 |
SCM
Sterling Capital Management
Charlotte,
North Carolina
|
-$76.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$69.2M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$64.5M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$59.1M |
NVS Hedge Fund Activity: Q3 2014 in Review
875 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2014, worth a combined $22.5B — up 2.4% from $22B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new NVS positions and 21 closed out — a net gain of 33 holders — while 315 added to existing stakes and 335 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $213M. The largest seller was Primecap Management, cutting an estimated $145M.
- 875 institutional investors held Novartis (NVS) as of Q3 2014, up from 848 in Q2 2014.
- Funds reported $22.5B of Novartis stock for Q3 2014, up 2.4% quarter-over-quarter.
- 54 funds opened new Novartis positions in Q3 2014 and 21 closed out, a net change of +33 holders.
- The largest Novartis buyer in Q3 2014 was Arrowstreet Capital, an estimated $213M added.
- The largest Novartis seller in Q3 2014 was Primecap Management, an estimated $145M sold.
Based on aggregated 13F filings for Q3 2014.